Our findings showed that HIC1 is closely related to the sensitivity of multiple anti-cancer drugs, especially small molecule inhibitors, including MEK inhibitors trametinib and PD−98059, indicating HIC1 plays a critical role in predicting the sensitivity of anti-cancer drugs. Here, HIC1 is linked to cancer.